Targeted therapy combined with immunotherapy <i>vs</i> trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer
TP and TB demonstrated similar PFS in both crude and PS-adjusted analyses. However, patients who derived benefits from TP therapy exceeding 90 days showed more sustained clinical advantages compared to TB. Our study suggests that for patients with MSS mCRC who respond to TP therapy in later-line treatments, this regimen could provide additional prolonged clinical benefits, which warrants further validation through large-scale cohort investigations.
Authors
- Shikai Wu (ORCID: https://orcid.org/0000-0002-0317-3148)
- Xuan Jin (ORCID: https://orcid.org/0000-0002-6478-2000)
- Zhigang Shen (ORCID: https://orcid.org/0000-0002-4121-5716)
- Xiaoyan Wang (ORCID: https://orcid.org/0000-0002-0800-5864)
- Xiaoyun Wang (ORCID: https://orcid.org/0000-0002-3052-8979)
- Tao Song (ORCID: https://orcid.org/0000-0001-7370-4277)
- Zhao Gao
Institutions
- Peking University (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2025-08-05
- DOI
- https://doi.org/10.3748/wjg.v31.i29.109947
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05